Skip to main content

Table 1 The deregulated miRNAs that can be controlled by epigenetic drugs in human cancers

From: Regulation of microRNAs by epigenetics and their interplay involved in cancer

Epigenetically regulated miRNAs

Target protein

Cancer type

Epigenetic drug

Fold change

Citation

Down-regulated

     

miR-449

CDK6, CDC25A, c-MET

Breast cancer

DZNep + TSA

>20 folds

[50]

Hepatocellular carcinoma

TSA

10-30 folds

[31]

miR-125b

PIGF

Hepatocellular carcinoma

5-Aza-CdR

>2 folds

[51]

miR-126

VEGFA, PIK3R2

Bladder cancer

5-Aza-CdR + PBA

>10 folds

[52]

miR-127

BCL6

Bladder cancer and clear cell renal cell carcinomas

5-Aza-CdR + PBA/TSA

>10 folds

[5, 53]

miR-1-1

FOXP1, MET, HDAC4

Hepatocellular carcinoma

5-AzaC

>20 folds

[43]

miR-34

C-MYC, CDK6,

Lung cancer, melanomas and prostate cancer

5-Aza-CdR

>10 folds

[54, 55]

miR-181a,b, miR-200a,b,c, and miR-203

BMI1 and RING2

Prostate cancer

DZNep/5-Aza-CdR/SAHA

2-20 folds

[32]

miR-31

SRC, RAB27a, NIK and MET, RhoA and WAVE3

Melanoma

5-Aza-CdR/DZNep

>2 folds

[24]

Breast cancer

5-Aza-CdR or 5-Aza-CdR + TSA

>5 folds

[25]

miR-29

Mcl-1, DNMT3A, DNMT3B,SP1, Tcl-1, CDK6 and IGR1F

Aggressive B-Cell Lymphomas

DZNep + SAHA

2-10 folds

[10]

Chronic lymphocytic leukemia and acute myeloid leukemia

LBH589/SAHA/AR-42

2-5 fold

[15, 16]

miR-15a/miR-16

BCL-2 and MCL-1

Chronic lymphocytic leukemia

LBH589/SAHA

2-5 fold

[16]

miR-205

SIP1 and ZEP

Prostate cancer

5-Aza-CdR

>100 folds

[37]

miR-21

PDCD4, TPM1, and MARCKS

Prostate cancer

5-Aza-CdR

>2 folds

[37]

miR-370

IRS-1

Oral squamous cell carcinoma

5-Aza-CdR

2-20 folds

[56]

miR-373

MBD2

Hilar cholangiocarcinoma

5-Aza-CdR or 5-Aza-CdR + TSA

2-5 folds

[57]

miR-193b

ETS1, CCND1, PLAU

Prostate cancer

5-Aza-CdR + TSA

>2 folds

[58]

miR-132

HB-EGF,TALIN2

Prostate cancer

5-Aza-CdR or 5-Aza-CdR + TSA

>5 folds

[59]

miR-145

BNIP3, TNFSF10,PAK7

Prostate cancer and clear cell renal cell carcinomas

5-Aza-CdR or 5-Aza-CdR + TSA

>2 folds

[53, 60]

miR-141, miR-514

HGF, CDC42, RBX1, SLC2A1

Clear cell renal cell carcinomas

5-Aza-CdR + TSA

>2 folds

[53]

miR-335

SOX4, Rb1

Hepatocellular carcinoma

5-Aza-CdR + TSA

>2 folds

[61]

miR-205

BCL-w

Prostate cancer

5-Aza-CdR

2-5 folds

[62]

let-7 family

RAS

Nasopharyngeal carcinoma

Zebularine

2-100 folds

[63]

Up- regulated

     

miR-224

API-5

Hepatocellular carcinoma

C646

<50%

[36]

miR-17-92 Cluster

PTEN, BCL2L11, CDKN1A

Colorectal Cancer

SAHA or TSA

25%-67%

[64]

  1. DNMT inhibitors: 5-azacytidine (5-AzaC); 5-aza-2′-deoxycytidine(5-Aza-CdR); Zebularine.
  2. HDAC inhibitors: suberoylanilide hydroxamic acid (SAHA); trichostatin A (TSA); panobinostat(LBH589); phenylbutyrate (PBA); OSU-HDAC42(AR-42).
  3. HAT inhibitors: C646.
  4. HMT inhibitors: 3-deazaneplanocin A (DZNep).